Bioprocess development of antibody-drug conjugate production for cancer treatment

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design

(2018) Pamela A. Trail et al.   PHARMACOLOGY & THERAPEUTICS

Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates

(2017) Martin Pabst et al.   JOURNAL OF CONTROLLED RELEASE

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates

(2017) Alex R. Nanna et al.   Nature Communications

Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

(2017) Mohammad-Reza Nejadmoghaddam et al.   Scientific Reports

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

(2016) Paul A. Bunn et al.   Journal of Thoracic Oncology

Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC)

(2015) João P. M. Nunes et al.   CHEMICAL COMMUNICATIONS

An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety

(2015) Penelope M Drake et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

(2015) Christopher R. Behrens et al.   MOLECULAR PHARMACEUTICS

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios

(2015) Penny Bryant et al.   MOLECULAR PHARMACEUTICS

Maytansinoid–BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes

(2015) Nathan Fishkin   MOLECULAR PHARMACEUTICS

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates

(2015) Shi Xu   PHARMACEUTICAL RESEARCH

Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate

(2015) Julien Marcoux et al.   PROTEIN SCIENCE

Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment

(2014) François Debaene et al.   ANALYTICAL CHEMISTRY

Bridging Disulfides for Stable and Defined Antibody Drug Conjugates

(2014) George Badescu et al.   BIOCONJUGATE CHEMISTRY

Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload

(2014) Yilma T. Adem et al.   BIOCONJUGATE CHEMISTRY

Antibody–drug conjugates—A new wave of cancer drugs

(2014) Hervé Bouchard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging

(2014) Felix F. Schumacher et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Brentuximab vedotin

(2012) Anas Younes et al.   NATURE REVIEWS DRUG DISCOVERY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage

(2011) Brenda A. Kellogg et al.   BIOCONJUGATE CHEMISTRY

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase

(2010) Simone Jeger et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates for cancer: poised to deliver?

(2010) Bethan Hughes   NATURE REVIEWS DRUG DISCOVERY

Molecularly Defined Antibody Conjugation through a Selenocysteine Interface

(2009) Thomas Hofer et al.   BIOCHEMISTRY

Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection

(2009) Elizabeth Boeggeman et al.   BIOCONJUGATE CHEMISTRY

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

(2008) Ezogelin Oflazoglu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

(2008) Jagath R. Junutula et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY